Sysmex in agreement to distribute AdnaGen cancer diagnostic tests
in Europe
10 February 2009
Sysmex Europe GmbH and AdnaGen AG have entered into a
non-exclusive European distribution agreement for AdnaGen
proprietary CE-certified diagnostics as well as their
research use only (RUO) products. The tests are based on the
capture of circulating tumour cells (CTCs) from blood and
subsequent detection and profiling of tumour markers.
Cancer diagnostics is an evolving and rapidly growing segment of
in-vitro diagnostics. Following cardiovascular disorders, cancer is
the second most deadly condition, affecting over 25 million people
worldwide, with more than 10 million new cases diagnosed annually. There
is a need for improved diagnostics capable of enabling earlier diagnosis
and guiding better disease treatment and management.
The AdnaTest diagnostic and analytical products for breast and
colon cancer are aimed at improving cancer prognosis and patient
management. The tests are based on immunomagnetic selection of tumour
cells from blood followed by detection of tumour-specific markers using
RT-PCR amplification techniques. An advantage of the proprietary AdnaGen
tests is versatility; the detection of a broad range of molecular
biomarkers is possible enabling rapid application to new diseases and
targeted drug development.
The AdnaTest addresses several clinical needs including:
Improvement of determination of disease prognosis, providing insight
into which drug targets may be present on metastases, giving rapid
feedback on which therapies are providing the desired clinical benefit
as well as early detection of disease recurrence.
Alexander L. Weis, PhD, Chairman of the Supervisory Board of AdnaGen
commented, “AdnaGen is very excited about its new relationship with
Sysmex. We believe that the combination of the advantages provided by
our AdnaGen products and the impressive distribution network of Sysmex
will greatly accelerate the commercialization of our products and the
reach of Sysmex in the oncology diagnostic and analytical marketplace.”
Bookmark this page